Abstract
Clomiphene, a selective estrogen receptor modulator (SERM), has been used for the treatment of anovulation for more than 50 years. However, since (E)-clomiphene ((E)-Clom) and its metabolites are eliminated primarily via Cytochrome P450 (CYP) 2D6 and CYP3A4, exposure can be affected by CYP2D6 polymorphisms and concomitant use with CYP inhibitors. Thus, clomiphene therapy may be susceptible to drug–gene interactions (DGIs), drug–drug interactions (DDIs) and drug–drug–gene interactions (DDGIs). Physiologically based pharmacokinetic (PBPK) modeling is a tool to quantify such DGI and DD(G)I scenarios. This study aimed to develop a whole-body PBPK model of (E)-Clom including three important metabolites to describe and predict DGI and DD(G)I effects. Model performance was evaluated both graphically and by calculating quantitative measures. Here, 90% of predicted Cmax and 80% of AUClast values were within two-fold of the corresponding observed value for DGIs and DD(G)Is with clarithromycin and paroxetine. The model also revealed quantitative contributions of different CYP enzymes to the involved metabolic pathways of (E)-Clom and its metabolites. The developed PBPK model can be employed to assess the exposure of (E)-Clom and its active metabolites in as-yet unexplored DD(G)I scenarios in future studies.
Funder
European Commission Horizon 2020 UPGx
Robert Bosch Stiftung, Stuttgart, Germany
German Federal Ministry of Education and Research
Reference80 articles.
1. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome;Legro;N. Engl. J. Med.,2007
2. The prevalence of polycystic ovary syndrome: A brief systematic review;Deswal;J. Hum. Reprod. Sci.,2022
3. Fertility treatment in women with polycystic ovary syndrome: A decision analysis of different oral ovulation induction agents;Jungheim;Fertil. Steril.,2010
4. (2021, August 12). European Medicines Agency (2018) Assessment Report EnCyzix. Available online: https://www.ema.europa.eu/en/documents/assessment-report/encyzix-epar-public-assessment-report_en.pdf.
5. Genetic polymorphism of cytochrome p450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites;Kerb;Hum. Mol. Genet.,2012
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献